Envoy Medical Inc. received written notification from Nasdaq confirming compliance with Listing Rule 5550(b)(2) through permitted alternatives under Listing Rule 5550(b). The company previously received a notice on February 25, 2025, indicating non-compliance with the minimum Market Value of Listed Securities (MVLS) of $35 million. Compliance was regained following the implementation of strategic financing initiatives and a substantial strengthening of the company's balance sheet. Envoy Medical believes it has an achievable plan to maintain compliance and looks forward to remaining listed on the Nasdaq Capital Market under the symbol COCH. The company will be subject to a discretionary panel monitor for a period of one year from February 12, 2026, as per Nasdaq Listing Rule 5815(d)(4)(B). Envoy Medical develops fully implanted hearing solutions, including the commercially available Esteem active middle ear implant and the investigational Acclaim cochlear implant, which received FDA Breakthrough Device Designation in 2019.